12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ITI-214: Phase I data

A double-blind, placebo-controlled Phase I trial in 70 healthy volunteers showed that single ascending-doses of oral ITI-214 were well tolerated. Intra-Cellular declined to...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >